Current therapies to manage DN are limited to the control of blood pressure and gluse levels, and treatment with angiotensin-receptor blockers (ARBs) and angiotensin-converting-enzyme (ACE) inhibitors may partially ameliorate proteinuria and delay progression to ESRD (Gregg et al., 2014; Worldwide trends in diabe, 2016). The gene discussed is ACE; the disease is liver dysplastic nodule.